Lifesci Capital Has Positive Outlook of CMPS Q2 Earnings

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Lifesci Capital boosted their Q2 2026 EPS estimates for shares of Compass Pathways in a research report issued to clients and investors on Tuesday, June 2nd. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings per share of ($0.35) for the quarter, up from their previous estimate of ($0.50). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($1.24) per share.

A number of other brokerages have also recently commented on CMPS. TD Cowen reiterated a “buy” rating on shares of Compass Pathways in a research report on Monday. BTIG Research reiterated a “buy” rating and issued a $14.00 target price on shares of Compass Pathways in a research report on Wednesday, May 13th. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. B. Riley Financial started coverage on shares of Compass Pathways in a research report on Friday, April 24th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Canaccord Genuity Group decreased their target price on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, March 26th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $21.36.

Compass Pathways Price Performance

Shares of NASDAQ:CMPS opened at $12.69 on Thursday. The stock has a market cap of $1.71 billion, a PE ratio of -4.03 and a beta of 2.50. The company’s fifty day moving average is $8.70 and its 200 day moving average is $7.30. Compass Pathways has a 52 week low of $2.25 and a 52 week high of $14.76. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15.

Institutional Investors Weigh In On Compass Pathways

A number of large investors have recently added to or reduced their stakes in CMPS. EverSource Wealth Advisors LLC grew its holdings in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after acquiring an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Compass Pathways in the 4th quarter worth $38,000. Parallel Advisors LLC grew its holdings in Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after acquiring an additional 7,183 shares during the last quarter. Advisory Services Network LLC bought a new stake in Compass Pathways in the 3rd quarter worth $41,000. Finally, North Star Investment Management Corp. grew its holdings in Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after acquiring an additional 7,000 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.